Core Insights - Upstream Bio, Inc. is set to report top-line results from the Phase 2 VALIANT trial of verekitug, a treatment targeting the TSLP receptor, on February 11, 2026 [1][2] Group 1: Company Overview - Upstream Bio is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [4] - The company is advancing verekitug, the only known antagonist in clinical development targeting the TSLP receptor, which is involved in inflammatory responses [4] - Upstream Bio aims to address significant unmet needs in patients underserved by current standard care through its development of verekitug [4] Group 2: VALIANT Trial Details - The VALIANT trial is a Phase 2 global, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of verekitug in 478 patients with severe asthma [2] - Participants in the trial were divided into four groups, receiving either 100 mg or 400 mg of verekitug every 24 weeks, 100 mg every 12 weeks, or a placebo, administered subcutaneously [2]

As filed with the U.S. Securities and Exchange Commission on February 10, 2026. Registration No. 333-292285 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ––––––––––––––––––––––––––––––––––––––– AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ––––––––––––––––––––––––––––––––––––––– Brookline Capital Acquisition Corp II (Exact name of registrant as specified in its charter) ––––––––––––––––––––––––––––––––––––––– | Cayman Islands | 6770 | N/A | | - ...

Core Insights - Septerna, Inc. has granted an inducement award to its Chief Legal Officer, Mark A. Wilson, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company's 2026 Inducement Plan [1][2] Group 1: Stock Option Details - The stock option has an exercise price of $25.41 per share, which is equal to Septerna's closing share price on February 6, 2026 [2] - The stock option will vest over four years, with 25% of the shares vesting on the one-year anniversary and the remaining 75% vesting in equal monthly installments over 36 months, contingent on Mr. Wilson's continuous employment [2] Group 2: Company Overview - Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, aiming to address significant unmet medical needs [3] - The company utilizes its proprietary Native Complex Platform to develop a diverse pipeline of novel oral small molecule drug candidates across various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases [3]

Market Overview - The US market is experiencing modest gains, with the Dow up approximately 350 points and the S&P 500 attempting to reach a new record close [1] - Consumer discretionary stocks are performing well despite retail sales data showing no growth for the holiday season, which was below the expected increase of 0.4% [1] - Spotify shares surged nearly 17% following strong subscriber growth and improved margins, marking its best gain in about a year [1] Retail Sales and Consumer Behavior - December retail sales data indicated flat year-over-year sales, contrasting with a 6.4% increase in holiday spending across all generations [1][2] - High-income households (earning $125,000 or more) increased their holiday spending by 29%, while mid and low-income cohorts reduced spending by about 4% [2] - The K-shaped economy is evident, with wealthier consumers driving spending while lower-income consumers focus on essentials [2] Company Earnings and Forecasts - CVS reported a strong fourth quarter, with revenue from healthcare benefits rising 10% to approximately $36 billion and pharmacy services revenue increasing by 9% to about $51 billion [5] - CVS's profit guidance for 2026 is set between $7 and $7.20 per share, with a cash forecast of $9 billion for the year [5][6] - Coca-Cola's shares fell over 1% after a disappointing forecast, while S&P Global's shares dropped 8% due to a weak outlook [1] Streaming Industry Insights - Spotify's record user growth is attributed to innovative marketing strategies like its Wrapped campaign and curated playlists [1][45] - The company aims to maintain its market dominance by continuously engaging new users and enhancing its service offerings [45] Biotech Sector Developments - The biotech industry is expected to see an increase in M&A activity, with companies like Halosime actively acquiring startups to enhance drug delivery technologies [4] - Halosime's recent acquisitions focus on subcutaneous drug delivery, which could transform patient care by reducing the need for lengthy infusion treatments [4] Travel and Hospitality Sector - Marriott reported strong demand for travel, particularly in the luxury segment, despite challenges from government shutdowns affecting business travel [27][29] - The company anticipates continued growth in revenue per available room (RevPAR) and has a robust pipeline of new hotel openings [29]

Core Viewpoint - Exelixis, Inc. is highlighted as a promising healthcare stock under $50, with a recent price target revision by Barclays indicating a positive outlook for the company [1]. Group 1: Financial Updates - Barclays revised the price target for Exelixis, Inc. to $44 from $41 while maintaining an Equal Weight rating [1]. Group 2: Drug Development - Exelixis announced the acceptance of its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for treating adult patients with metastatic colorectal cancer [2]. - The FDA has assigned a standard review for zanzalintinib, with a target action date of December 3, 2026 [3]. - Dana T. Aftab, Ph.D., emphasized the potential of zanzalintinib to provide a novel mechanism of action for previously treated metastatic colorectal cancer patients if approved [3]. Group 3: Company Overview - Exelixis, Inc. focuses on discovering, developing, and commercializing new medicines for difficult-to-treat cancers, with a product portfolio that includes cabometyx, cometriq, and cotellic [4].

Core Insights - Exousia Pro, Inc. is accelerating its healthcare vertical through the execution of a third Letter of Intent to acquire a telehealth organization, enhancing its strategic position in the biotechnology sector [1][2]. Strategic Infrastructure & Direct-to-Patient Network - The acquisition of established telehealth platforms is a cornerstone of Exousia's strategy to create a vertically integrated health ecosystem, providing independent revenue streams and access to a built-in network of patients and providers [2]. - By utilizing its telehealth channels for marketing high-value clinical products, Exousia anticipates a significantly lower Customer Acquisition Cost (CAC), leading to higher margins and faster market penetration [2]. Specialized 3rd Acquisition: Institutional Scale - The target organization for the latest acquisition operates in a prestigious niche, collaborating with University-connected hospitals across the U.S. and has a proprietary model that can reduce hospital prescription costs by up to 50% [3]. The Revenue Model: Due Diligence & Timeline Update - Management is finalizing due diligence for the first two acquisitions, with the execution date pushed to later this month due to the thorough verification process aimed at ensuring long-term shareholder value [4]. - Due diligence materials for the third acquisition are currently under active review [4]. Leadership Perspective - The President of Exousia Pro, Inc. emphasized the aggressive scaling of healthcare infrastructure through targeted acquisitions, highlighting the significant standalone revenue and access to a high-intent audience for delivering cancer screening tests and nutraceuticals [5]. Proprietary Nutraceutical Products - Exousia Pro, Inc. focuses on advanced cancer screening tests and proprietary nutraceutical products, aiming to bridge the gap between clinical innovation and patient access through its expanding telehealth division [5][8]. Performance-Based Earnings - The company typically earns 10% of the total savings generated for hospitals over a four-year period, with most commissions realized within the first two years, ensuring robust and predictable cash flow [9].

Core Insights - FibroBiologics, a clinical-stage biotechnology company, focuses on developing therapeutics for chronic diseases using fibroblasts and holds over 270 patents [1][6] - The company's CEO, Pete O'Heeron, will speak at the A4LI's H-SPAN Summit, emphasizing the importance of longevity research and its alignment with FibroBiologics' mission [3][5] Company Overview - FibroBiologics is based in Houston and is dedicated to creating treatments and potential cures for chronic diseases through fibroblast technology [6] - The company has a diverse patent portfolio covering various clinical pathways, including wound healing, multiple sclerosis, and cancer [6] Industry Context - The A4LI's H-SPAN Summit is a significant event aimed at promoting legislative and scientific initiatives for healthier human lifespans, featuring leaders and innovators from various sectors [2][4] - The summit will focus on cutting-edge longevity research, innovation policy frameworks, and advocacy efforts with Congress to enhance national healthspan priorities [4]

Company Overview - KDventures AB, a Nordic investment company specialized in life sciences, has a 33% ownership stake in SVF Vaccines, which is focused on developing DNA vaccines and immunotherapies based on proprietary technology from Karolinska Institutet [5][6]. Leadership Appointment - SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition of its lead vaccine candidate SVF-001 into phase 1 clinical development [1][2]. - Nassaji brings nearly two decades of experience in big pharma, biotech, and healthcare innovation, with a strong background in clinical development, capital strategy, and business development [3]. Strategic Focus - Raheleh Nassaji emphasized the importance of disciplined clinical execution, building a strong financing and partnering strategy, and positioning SVF Vaccines for long-term value creation as the company generates early clinical data [4]. - The leadership change comes at a critical stage for SVF Vaccines as it prepares to enter first-in-human clinical trials with SVF-001 [2][5].

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. Cambridge, UK, 10 February 2026 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that Dr Amy Walker has been appointed as ...

Core Viewpoint - Polyrizon Ltd. has signed a non-binding Memorandum of Understanding (MOU) to acquire a 51% stake in Arrow Aviation, a high-growth private aviation company, for approximately $5.8 million, marking a strategic entry into the private aviation sector [1][3]. Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing intranasal protective solutions, including innovative medical device hydrogels delivered as nasal sprays [5]. - Arrow Aviation, with annual unaudited revenues of approximately $19 million and adjusted EBITDA of around $3 million, provides private aviation services, operating a fleet of executive jets and catering to both leisure and business clients [2]. Strategic Rationale - The acquisition is seen as a diversification opportunity for Polyrizon, allowing the company to leverage its financial position to enter the growing private aviation market, projected to reach $41.38 billion by 2030 [3]. - The proposed transaction includes arrangements for a third-party transfer of a Hawker 800 aircraft valued at $3.5 million and the forgiveness of outstanding debts by existing Arrow Aviation shareholders in exchange for convertible notes from Polyrizon [3]. Transaction Details - A definitive agreement is expected to be signed within 30 days of the MOU, subject to due diligence, with the closing of the acquisition anticipated to follow customary closing conditions [4].